Marshall Wace, LLP Neurocrine Biosciences Inc Transaction History

Marshall Wace, LLP

$90.8 Billion
Q3 2025

A detailed history of Marshall Wace, LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 97,289 shares of NBIX stock, worth $14.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

97,289

Previous 41,649 133.59%

Holding current value

$14.1 Million

Previous $5.23 Million 160.93%

% of portfolio

0.02%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$123.98 - $146.67 $6.9 Million - $8.16 Million	55,640 Added 133.59%	97,289 $13.7 Million
Q2 2025 Aug 13, 2025	BUY	$87.54 - $128.18 $3.65 Million - $5.34 Million	41,649 New	41,649 $5.23 Million
Q4 2024 Feb 13, 2025	BUY	$111.62 - $139.44 $270,678 - $338,142	2,425 New	2,425 $331,000
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $4.3 Million - $4.74 Million	32,976 New	32,976 $4.55 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $12.4 Million - $16.3 Million	132,237 Added 434.33%	162,683 $16.5 Million

Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $3.25 Million - $3.87 Million	30,446 New	30,446 $3.64 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $764,564 - $1 Million	-10,553 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $840,546 - $1.12 Million	10,553 New	10,553 $898,000
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $6.92 Million - $9.44 Million	-79,044 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $5.9 Million - $7.36 Million	-67,899 Reduced 46.21%	79,044 $7.58 Million
Q3 2020 Nov 16, 2020	BUY	$96.16 - $135.15 $14.1 Million - $19.9 Million	146,943 New	146,943 $14.1 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $330,108 - $499,975	-4,395 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $5.4 Million - $7.37 Million	-62,171 Reduced 93.4%	4,395 $473,000
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $5.58 Million - $6.76 Million	66,566 New	66,566 $6 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $27.1 Million - $34.2 Million	-375,076 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$69.31 - $91.53 $23 Million - $30.4 Million	-332,399 Reduced 46.98%	375,076 $33 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $42.8 Million - $78 Million	626,995 Added 779.07%	707,475 $50.5 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $7.96 Million - $10.1 Million	80,480 New	80,480 $9.9 Million
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $613,243 - $863,182	-8,144 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $617,966 - $752,749	8,144 New	8,144 $675,000

Others Institutions Holding NBIX

# of Institutions

727

Shares Held

102M

Call Options Held

230K

Put Options Held

477K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Neurocrine Biosciences Inc Transaction History